Objectives
The use of transcatheter aortic valve implantation (TAVI) for high-risk or inoperable patients was introduced in the 2000s for treatment of aortic valve stenosis patients. During the last years, there has been a dramatic increase in TAVI procedures. TAVI programs are implemented in numerous cardiac centers. This paper describes a single center experience with its first 140 TAVI procedures.
Methods
This study included the first 140 patients who were scheduled for either transfemoral (TF-TAVI) or transaortic (TA-TAVI) aortic valve implantation at ŞİFA University Hospital, using the Edwards SAPIEN XT™ (ESV), Boston LOTUS valve™ (BLV), Medtronic Corevalve and EVOLUTE-R™ (MCV). The indication for TAVI was unacceptable high predicted risk associated with open heart valve surgery. Patients with adequate diameter of iliac arteries were scheduled for TF-TAVI, otherwise TA-TAVI was preferred. After TAVI, dual antiplatelet therapy was recommended with aspirin, 100 mg daily indefinitely and clopidogrel, 75 mg daily (for 3 months).
Methods
This study included the first 140 patients who were scheduled for either transfemoral (TF-TAVI) or transaortic (TA-TAVI) aortic valve implantation at ŞİFA University Hospital, using the Edwards SAPIEN XT™ (ESV), Boston LOTUS valve™ (BLV), Medtronic Corevalve and EVOLUTE-R™ (MCV). The indication for TAVI was unacceptable high predicted risk associated with open heart valve surgery. Patients with adequate diameter of iliac arteries were scheduled for TF-TAVI, otherwise TA-TAVI was preferred. After TAVI, dual antiplatelet therapy was recommended with aspirin, 100 mg daily indefinitely and clopidogrel, 75 mg daily (for 3 months).
Stay updated, free articles. Join our Telegram channel
Full access? Get Clinical Tree
